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Aspergillusmarkers are becoming increasingly important for the early diagnosis of invasive aspergillosis. The
kinetics of release of these surrogate markers, however, is largely unknown. We investigated the release of
-(1-5)-galactofuranosyl (galf) antigens (Platelia Aspergillus), 1,3--D-glucan (BG) (Fungitell), and DNA
(PCR) in an in vitro model of Aspergillus fumigatus. The results showed that release is correlated to the growth
phase of the fungus, which depends on available nutrients. Whereas galf antigens and BG are released during
logarithmic growth, DNA is released only after mycelium breakdown. During early logarithmic growth, galf
antigens seem to be released somewhat earlier than BG. Furthermore, galf antigen concentrations of more than
120,000 times the serum cutoff value (0.5 ng/ml) can be measured, while BG concentrations reach a value only
978 times the serum cutoff value (60 pg/ml). During lytical growth, release of galf antigens further increased
to a maximum level, which depended on pH. After that, the concentration of galf antigens stayed high (pH 7.4)
or decreased to zero within 4 days (pH 5.0). In contrast to galf antigens, BG concentration decreased after 1
day of growth. The decrease of galf components seems to be due to the enzyme -galactofuranosidase, which
is able to destroy galf epitopes and whose activity fluctuates in the culture filtrates in parallel with galf antigen
concentration. Fungal DNA seems to be released only due to autolysis caused by nutrient limitation. In
conclusion, several factors clearly influence the release of surrogate markers in vitro. These same factors might
also play a role at the infection site of Aspergillus disease in humans.
Invasive aspergillosis (IA) has become a leading cause of
death among immunocompromised hosts, including transplant
patients, those treated for hematological malignancy, and
those treated with high-dose corticosteroids (41, 49). In addi-
tion, IA is increasingly observed in the nonneutropenic phase
after hematopoietic stem cell transplantation and in nonclassic
settings, such as intensive care units with critically ill patients
(13, 16). The high mortality is due partly to the difficulty in
establishing a diagnosis at an early stage of infection, since
presenting symptoms are nonspecific and sensitivity of cultures
is low. Techniques to improve timely diagnosis have focused on
the detection of circulating surrogate markers released by the
fungus (43, 45, 50). With the development of nonculture-based
methods, such as PCR and antigen detection, circulating mark-
ers can be detected at an early stage of infection in patients
with invasive disease (12, 27, 28).
The commercially available sandwich enzyme-linked immu-
nosorbent assay (ELISA) (Platelia Aspergillus [PA]; Bio-Rad,
Marnes-la-Coquette, France) is based on the rat immunoglob-
ulin M monoclonal antibody EB-A2, which binds the -(1-5)-
galactofuranosyl (galf) side chains of the Aspergillus galacto-
mannan (GM) molecule (24, 50, 51). In addition to GM, fungal
glycoproteins also react with the EB-A2 antibody, including
phospholipase C and phytase, which were shown to have only
one terminal galactofuranose unit that was essential for bind-
ing with the EB-A2 antibody (24, 48). These findings implicate
that the so-called “GM antigen” is not a single molecule but a
family of molecules for which expression could be modulated
by the immediate fungal environment (34). However, the ac-
tual galf antigens that circulate in vivo in the body fluids of
patients have not been characterized. Furthermore, there are
several problems related to antigen detection. In some patients
with proven IA, circulating antigen is not detected despite
repeated sampling (false negative) (55). Also, the performance
of antigen detection might be reduced in patients receiving
antifungal prophylaxis. These and other factors that influence
the release of galf antigens, including their leakage from the
site of infection into the blood and their bonding to substances
present in the blood, were recently explored (31).
In contrast to the PA ELISA, there is no standardized PCR
method for the detection of Aspergillus DNA for early diagno-
sis of IA. Whereas most methods show good sensitivity and
specificity in experimental settings, unresolved issues, such as
the optimal specimen (e.g., whole-blood, serum, plasma, and
bronchoalveolar lavage specimens) and DNA extraction
method, are probably major causes of variability in perfor-
mance in clinical studies (5, 6, 18, 26). False-negative results
are especially often found in patients with proven IA (6), which
might be correlated with antifungal drug treatment.
A third promising nonculture-based diagnostic test detects
circulating 1,3--D-glucan (BG). BG is a cell wall component
of most medically important fungi, including Aspergillus fu-
migatus (35, 36). Furthermore, A. fumigatus releases BG into
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the culture fluid in parallel with in vitro fungal growth (33) and
can be quantified spectrophotometrically by activation of fac-
tor G, a coagulation factor of the horseshoe crab (35). A
recently FDA-approved commercial method for the deter-
mination of BG has become available (Fungitell, formerly
Glucatell; Associates of Cape Cod) (38). There are only a
limited number of clinical studies published, and a definitive
cutoff value for the diagnosis of IA remains to be established
(37, 38, 42).
At present, there is insufficient understanding of the in vitro
and in vivo kinetics of circulating galf antigens, BG, and fungal
DNA. Recently, an in vitro study of the release of galf antigens
by A. fumigatus in relation to the fungal biomass (20) showed
that the amounts of galf antigens released in the culture super-
natant were not different for strains from circulating antigen-
positive (CAG) and circulating antigen-negative (CAG) IA
patients. Other causes for negative antigenemia could be the
reduced release of galf antigens due to environmental factors,
such as pH, and reduced availability of nutrients at the site of
infection. Because the kinetics of release of surrogate markers is
largely unknown, we used the same in vitro model to study and
compare the release of galf antigens, DNA, and BG by A. fumiga-
tus strains from different patients.
MATERIALS AND METHODS
Fungal strains and culture conditions. A. fumigatus strains from a CAG and
a CAG patient were cultured in flasks containing yeast nitrogen base (YNB)
liquid medium with different glucose concentrations (5, 25, and 100 mM) and at
different pHs (5.0 to 7.4). The medium was buffered with MOPS (morpholin-
opropanesulfonic acid) (170 mM) or MES (morpholineethanesulfonic acid) (100
mM) or not buffered. Each growth experiment was performed in duplicate and
with one CAG (AZN 4684) and one CAG (AZN 4565) strain. The cultures
were incubated for a maximum of 9 days at 37°C and 160 rpm after inoculation
with spores to a final concentration of 106 to 107 spores/ml. For each time
measurement, one Erlenmeyer flask (500 ml) containing 200 ml of culture was
used. The mycelium was harvested by filtration on a filter (0.8 m; Schleicher &
Schuell) and freeze-dried to determine the biomass. The culture filtrate was used
for the PA ELISA, pH and glucose measurements, the -galactofuranosidase
assay, and detection of DNA and BG. Furthermore, the release of galf antigens,
BG, and DNA was also measured in one Erlenmeyer flask by taking (sterile)
samples at serial time points, followed by filtration of the sample (0.2 m
cellulose acetate; Schleicher & Schuell).
PA ELISA. The culture filtrate samples were serially diluted in water for
detection of reactivity by the PA ELISA. Each plate contained a standard
calibration curve (0 to 15 ng/ml purified GM) in order to use the ELISA
quantitatively. The PA ELISA was performed according to the manufacturer’s
instructions. Briefly, 50 l of a reaction mixture containing horseradish peroxi-
dase-conjugated anti-GM monoclonal antibody EB-A2 was added to each well of
a microtiter plate coated with the same monoclonal antibody EB-A2, followed by
the addition of 50 l of pretreated sample. After 90 min of incubation at 37°C,
the plates were washed five times with washing buffer before 200 l of buffer
containing tetramethylbenzidine solution was added. Then, the plates were in-
cubated for another 30 min in the dark at room temperature, followed by the
addition of 100 l of 1.5 N sulfuric acid to stop the reaction. The optical density
(OD) was read at 450 and 620 nm. A test sample was considered positive when
the OD at 450 nm was higher than that of the cutoff sample (i.e., 0.5 ng GM).
When testing different dilutions, the OD value closest to the OD value of the
cutoff sample (i.e., 0.5 ng GM; R4) was interpolated in the calibration curve, and
the total PA reactivity was expressed as the amount of GM in ng/ml (in addition
to GM, actual PA reactivity in culture filtrates comes from several galf compo-
nents; however, only purified GM was available for quantification).
Fungitell BG assay. The culture filtrate samples were serially diluted in glucan-
free reagent grade water (RGW) for detection of BG by the Fungitell test kit
(Associates of Cape Cod, Falmouth, Mass.) in a kinetic, chromogenic format as
recommended by the manufacturer. All assays were performed in duplicate.
Briefly, 25-l samples of the standards (100 to 6.25 pg/ml pure pachyman, a
linear BG) and unknown pretreated samples were added to each well of a
microtiter plate. Unknown samples (5 l) were pretreated for 10 min at 37°C
with an alkaline reagent (20 l; 0.125 M KOH/0.6 M KCl). Fungitell reagent
(lyophilized BG-specific Limulus amebocyte lysate) was reconstituted with 2.8 ml
of RGW, followed by 2.8 ml of pyrosol reconstitution buffer (2 M Tris HCl, pH
7.4), and 100 l of this mixture was added to each sample. An OD405 was read
for 40 min at 37°C, using an Anthos HT-3 plate reader and MikroWin software
(Mikrotek Laborsysteme GmbH), and the concentration in each unknown sam-
ple was calculated using the calibration curve after the standards were multiplied
by 5, so that the range was from 500 to 31.25 pg/ml. When absorbance was
outside the range of the standard curve, the samples were diluted in RGW and
tested again.
Glucose assay. Glucose concentration was measured enzymatically by coupling
the glucose oxidase reaction to the peroxidase reaction. Culture filtrate samples
(serially diluted in water) and glucose standard samples (0.05 to 1.2 mM glucose)
were analyzed by taking 100 l of sample and by mixing this with 1 ml of reagent
containing Na2HPO4 · 2H2O (13.6 g/liter), NaH2PO4 · H2O (7.2 g/liter), glucose
oxidase (750 U), peroxidase (150 U), and o-dianisidine dihydrochloride (39.4
mg/liter). After 45 min of incubation at room temperature, the formed brown-
colored product (oxidized o-dianisidine) was measured spectrophotometrically
at 450 nm. The A450 of the unknown samples was corrected for the blank
(diluted) culture medium without glucose, and the amount of glucose was cal-
culated from the standard curve.
-Galactofuranosidase assay. -Galactofuranosidase activity was determined
by measuring (in microtiter plates) the hydrolysis of p-nitrophenyl--D-galacto-
furanoside (PNP-galf; Sigma) following incubation at 37°C and pH 4.0 for 1.5 h.
The reaction was started by the addition of 60 l of culture filtrate to 1 mM of
substrate in a total volume of 100 l 100 mM sodium acetate buffer, pH 4.0. The
reaction was terminated with 200 l of stop solution containing 0.25 M Na2CO3
and 0.25 M NaHCO3. The yellow-colored product (p-nitrophenol) was measured
spectrophotometrically at 405 nm. One enzyme unit is defined as the amount
required to hydrolyze 1 mol of substrate min1 under these conditions, and
p-nitrophenol (Sigma) was used for the standard curve. Different blanks were
used, including water and culture medium.
DNA detection. DNA extraction of 1-ml culture filtrate samples was performed
with and without physical disruption, using MagNA lyser green 1.4-mm ceramic
beads (MagNA lyser; Roche), for two cycles of 20 s at 6,500 rpm, followed by
isolation with the MagNA Pure LC apparatus (Roche Biochemicals). The total
nucleic acid large-volume isolation kit (Roche Biochemicals) was used. We used
a starting volume of 1,000 l eluted in 50 l, and 10 l was used for the PCR. A.
fumigatus DNA was detected with a previously published PCR protocol which
amplifies a 363-bp fragment of the Aspergillus 18S rRNA gene (30).
RESULTS
General growth characteristics. Growth on glucose resulted
in an associated drop in pH when the medium was not buff-
ered, followed by a pH increase when glucose became limited
(Fig. 1A to C). During the logarithmic growth phase, glucose
consumption was correlated to biomass production. Glucose
became limited within 17 h (5 mM) or after 1 and 3 days (25
and 100 mM glucose, respectively). In order to study the effect
of glucose limitation, the 5 mM concentration (also human
blood values) was used for further studies. The effects of dif-
ferent pHs at this glucose concentration were tested (Fig. 2 and
3). In all cases, the maximum dry weight was about 0.4 to 0.5
mg/ml, which was reached within 17 h, the same time needed
for glucose consumption. CAG and CAG A. fumigatus
strains gave similar results. Glucose limitation initiated the
lytical phase, which is shown by the decrease of dry weight (Fig.
2 and 3; glucose concentrations are not shown but were 0
within 1 day of growth). Nine days after glucose became lim-
ited, the mycelium seemed to be broken down entirely in most
cultures. However, the fungus was still viable after being trans-
ferred to a fresh medium.
Release of galf antigens. During the logarithmic growth
phase, when glucose was consumed (values not shown), galf
antigens were released in the culture supernatant (Fig. 2 and
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3). After glucose became limited (after 1 day of growth), PA
ELISA reactivity further increased, followed by a decrease.
The maximum PA ELISA reactivities varied between the dif-
ferent culture conditions. At these maximum levels, the pH
was 7.1 for the culture that started at pH 7.4 and pH 4.4 for the
culture that started at pH 6.3 (values not shown). PA ELISA
reactivity was the highest when pH was 7.1 to 7.4 (about 60
g/ml) (Fig. 2 and 3) and lower when pHs were 4.4 (7.5 g/ml)
(Fig. 2) and 5.0 (10.9 g/ml) (Fig. 3). During this lytical phase,
PA ELISA reactivity reached the maximum value after 40 h
(pH 5 and lower) or after 4 days (pH 7.1) and more than 7 days
(pH 7.4), followed by a decrease. Galf antigens became unde-
tectable within 4 days at low pH. In contrast, at pH 7.4, PA
ELISA reactivity (expressed as GM concentration) decreased
only slightly (Fig. 3).
Release of Aspergillus DNA. Aspergillus DNA was not de-
tected in the culture supernatant during logarithmic growth
(Tables 1 and 2 and Fig. 2 and 3), indicating that DNA was not
FIG. 1. Growth of A. fumigatus (CAG strain) on YNB supple-
mented with 5 mM (—), 25 mM (- - -), or 100 mM (– –) of glucose as
the carbon source. The medium was not buffered, and the initial pH
was 6.3 to 6.8. (A) ■, dry weight (mg/ml). (B) Œ, glucose concentration
in culture filtrate (mM). (C) F, pH of culture filtrate.
FIG. 2. Growth of A. fumigatus on YNB medium supplemented
with 5 mM of glucose as the carbon source. Each line is the mean value
of a CAG and a CAG strain. Media were not buffered, and the
initial pH was 7.4 (—) or pH 6.3 (- - -). (■) Dry weight (mg/ml); (E)
GM (g/ml), i.e., PA ELISA reactivity due to galf antigens.
FIG. 3. Growth of A. fumigatus on YNB medium supplemented
with 5 mM of glucose as the carbon source. Each line is the mean value
of a CAG and a CAG strain. Media were buffered with MES at pH
7.4 (—) or pH 5.0 (- - -). (■) Dry weight (mg/ml); (E) GM (g/ml), i.e.,
PA ELISA reactivity of the supernatant due to galf antigens.
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released by the fungus. DNA was detected only during the
lytical phase, which corresponded with autolysis of the fungus
due to lack of nutrients (i.e., carbon source). These positive
samples were negative after mechanical disruption with beads
(MagNA lyser; Roche), which indicates that pretreatment re-
sults in loss of “free” DNA. Furthermore, DNA was detected
in pretreated mycelial samples (positive control) but not in any
untreated mycelial samples, indicating that pretreatment was
required to release the fungal DNA from the mycelium.
Release of BG. Like PA ELISA-reactive components, BG
was released during logarithmic growth in the culture medium,
as shown in Table 1. BG increased to a maximum, ranging
from 914 to 1,351 pg/ml, after about 1 day of growth with 5 mM
of glucose and at different pHs (mediums I to IV) and was
followed by a decrease. After the first decrease, the BG level
showed a second fluctuation at all pHs. However, these abso-
lute values are not much higher than background values at
time zero. Furthermore, BG levels reached approximately 16
times the serum cutoff value of 60 pg/ml while galf antigen
levels reached up to 118,840 times the serum cutoff value of 0.5
ng/ml GM (Table 1).
Release of BG compared to galf antigens and DNA. In order
to study the release of surrogate markers during early logarith-
mic growth under nutrient-sufficient conditions (i.e., 100 mM
glucose), BG, galf antigens, DNA, and the consumption of
glucose were measured during the first 40 h of growth of the
fungus in one Erlenmeyer flask. Compared to 5 mM of glucose,
the BG levels in the supernatant were much higher when the
fungus was grown at 100 mM of glucose, as shown in Fig. 4.
Whereas PA ELISA reactivity continued to increase to more
than 60,000 ng/ml GM or 120,000 times the serum cutoff value
of 0.5 ng/ml after 3 days of growth, when 100 mM glucose is
consumed (results shown only for first 40 h), BG reached a
maximum of 58,915 pg/ml or 978 times the serum cutoff value
after 1 day of growth, when about 30 mM of glucose had been
consumed, and decreased after that (Fig. 4A and B). Further-
more, the results of the PA ELISA, Fungitell assay, and PCR
are also shown in Table 3. The first indication of PA ELISA
reactivity was shown by an increase of the ELISA index (EI) of
0.5 after 2 h of growth. After 4 h of growth, the EI was three
times the EI at time zero. After 6 h of growth, the EI was 42
times higher than the value at time zero. The first indication of
BG release was more difficult to determine because the BG
background at time zero was 213.4 pg/ml (i.e., the mean of 0,
0, 76.1, and 777.5 pg/ml). After 2 h of growth, the BG value was
just above the highest background value, and the BG values
after 4 and 6 h of growth were below the highest background
value. Definitive release was measured after 8 h of growth
(Table 3). Aspergillus DNA was not detected in the culture
supernatant within the first 40 h of growth (Table 3).
In order to confirm that the decrease of BG was caused by
an enzyme that was released into the culture medium, the
following experiment was performed. A filtered supernatant
TABLE 1. Release of Aspergillus markers during in vitro growth
under different conditionsa
Mediumb t (h/days)
GM
(g/ml)
(n  2)
BG
(pg/ml)
(n  2)
GM
(ng/ml)c
BG
(pg/ml)d
DNA (PCR)
(CAG/
CAG)e
I 0 0.01 539 0 0 Neg/neg
16/0.7 3.70 1,351 7,380 14 Neg/neg
24/1.0 4.85 1,351 9,680 14 Neg/neg
40/1.7 7.47 664 14,920 2 Neg/pos
48/2.0 5.89 539 11,760 0 Neg/pos
72/3.0 1.80 1,039 3,580 8 Neg/pos
96/4.0 0.73 664 1,440 2 Pos/pos
168/7.0 0.01 40 0 0 Pos/pos
192/8.0 0.02 165 20 0 Pos/pos
216/9.0 0 102 0 0 Pos/pos
II 0 0.015 40 0 0 Neg/neg
4/0.2 0.025 290 20 4 Neg/neg
8/0.3 0.068 352 106 5 Neg/neg
16/0.7 1.71 914 3,390 15 Neg/neg
24/1.0 4.40 477 8,770 7 Neg/pos
40/1.7 10.10 477 20,170 7 Neg/pos
48/2.0 14.10 914 28,170 15 Neg/pos
72/3.0 37.50 914 74,970 15 Neg/pos
96/4.0 59.30 102 18,570 1 Neg/pos
168/7.0 14.70 0 29,370 0 Pos/pos
192/8.0 11.60 165 23,170 2 Pos/pos
216/9.0 11.40 40 22,770 0 Pos/pos
a Results are the mean values from two individual growth experiments (CAG
and CAG strains).
b Medium I, YNB medium with 5 mM of glucose. The medium was not
buffered and started at pH 6.3. Medium II, YNB medium with 5 mM of glucose.
The medium was not buffered and started at pH 7.4. See also Fig. 2.
c GM amount divided by the Platelia Aspergillus cutoff value (0.5 ng/ml) after
correction for value at time zero.
d BG amount divided by the Fungitell cutoff value (60 pg/ml) after correction
for value at time zero.
e Neg, negative; pos, positive.
TABLE 2. Release of Aspergillus markers during in vitro growth
under different conditionsa
Mediumb t (h/days)
GM
(g/ml)
(n  2)
BG
(pg/ml)
(n  2)
GM
(ng/ml)c
BG
(pg/ml)d
DNA (PCR)
(CAG/
CAG)e
III 0 0.015 44 0 0 Neg/neg
6/0.3 0.080 180 130 2.3 Neg/neg
22/0.9 4.67 588 9,307 9.1 Neg/neg
30/1.3 5.61 180 11,190 2.3 Neg/neg
47/1.9 10.90 1,064 21,770 17.0 Neg/pos
73/3.0 9.01 1,268 17,990 20.4 Neg/pos
95/4.0 1.08 112 2,130 1.1 Pos/pos
119/5.0 1.08 44 2,130 0 Neg/pos
167/7.0 0.570 248 1,110 3.4 Pos/pos
177/7.4 0.250 248 470 3.4 Neg/pos
200/8.3 0.150 44 270 0 Neg/pos
IV 0 0.010 215 0 0 Neg/neg
4/0.2 0.020 44 20 0 Neg/neg
6/0.3 0.052 84 Neg/neg
21/0.9 5.40 594 10,779 6 Neg/neg
25/1.0 7.08 1,177 14,140 16 Neg/neg
44/1.8 21.09 581 42,160 6 Pos/neg
73/3.0 31.50 492 62,980 5 Neg/neg
144/6.0 52.03 1,177 104,040 16 Neg/neg
177/7.4 59.43 819 118,840 10 Neg/neg
200/8.3 52.80 492 105,580 5 Neg/neg
a Results are the mean values from two individual growth experiments (CAG
and CAG strains).
b Medium III, YNB medium with 5 mM of glucose. The medium was buffered
at pH 5.0. Medium IV, YNB medium with 5 mM of glucose. The medium was
buffered at pH 7.4. See also Fig. 3.
c GM amount divided by the Platelia Aspergillus cutoff value (0.5 ng/ml) after
correction for value at time zero.
d BG amount divided by the Fungitell cutoff value (60 pg/ml) after correction
for value at time zero.
e Neg, negative; pos, positive.
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containing 51,814 pg/ml BG was boiled to reduce the enzyme
activity and then incubated for 24 h at 37°C. The remaining BG
concentration was measured at 4, 8, and 24 h. There was a 60%
(24 h) decrease in BG concentration in nonboiled supernatant
but no decrease of BG in the boiled supernatant.
-Galactofuranosidase activity. The galactofuranosidase ac-
tivity of the same culture filtrates as those shown in Fig. 2 and
3 was determined (Fig. 5 and 6). The enzyme activity was low
during logarithmic growth (about 0.2 to 0.4 U/liter) and in-
creased during the lytical phase, when the carbon source was
limited. Maximal activity was the lowest at higher pHs, being
1.4 U/liter at pH 7.1 to 7.4 (Fig. 5) and 2.6 U/liter at pH 7.4
(Fig. 6), and higher at low pHs, being 5.4 U/liter at pH 3.6 to
4.4 (Fig. 5) and 4.9 U/liter at pH 5.0 (Fig. 6). Activity was even
higher when grown on 25 mM of glucose at pH 5.0, being 11.6
U/liter. Furthermore, a strong increase in enzyme activity
seems to be correlated with a decrease in PA ELISA reactivity.
This phenomenon is most clearly seen with 25 mM of glucose
(Fig. 6). In order to confirm that -galactofuranosidase was
released into the culture medium and reduced the amount of
PA ELISA-reactive material, a filtered supernatant with a ga-
lactofuranosidase activity of 10 U/liter and a PA ELISA reac-
tivity of 2.1 g/ml GM was boiled to reduce the enzyme activity
and then incubated for 24 h at 37°C. The remaining enzyme
activity and PA ELISA reactivity were measured at 4, 8, and
24 h. The enzyme activity showed a 100% reduction due to the
boiling of the supernatant. There was a 69.8% (24 h) decrease
in PA ELISA reactivity in the nonboiled supernatant but no
reduction in PA ELISA reactivity in the boiled supernatant.
DISCUSSION
In this study, the glucose concentration and buffering capac-
ity of the medium determined the pH during fungal growth. In
Aspergillus species, growth in the presence of glucose is nor-
mally associated with organic acid production and an associ-
ated drop in pH (21). In addition, growth in the presence of
ammonium, the main nitrogen source of YNB, also decreased
medium pH because uptake of ammonia is accompanied by the
FIG. 4. (A) Release of galf antigens (expressed as the amount of
GM) and BG during growth of A. fumigatus on YNB medium supple-
mented with 100 mM of glucose as the carbon source in an Erlenmeyer
flask. Each line is the mean value of a CAG and a CAG (GM)
strain. The medium was buffered with MOPS at pH 7.4. (Œ) Glucose
concentration in culture filtrate (mM); (E) GM (ng/ml); (■) BG (pg/
ml). (B) Same as panel A, but the amounts of GM and BG are divided
by serum cutoff values (CV) 0.5 ng/ml and 60 pg/ml, respectively.
FIG. 5. Release of GM and -galactofuranosidase during growth of
A. fumigatus on YNB medium supplemented with 5 mM of glucose as
the carbon source. Each line is the mean value of a CAG and a
CAG strain. Media were not buffered and started at pH 7.4 (—) or
pH 6.3 (- - -). () -Galactofuranosidase activity (U/liter); (E) GM
(g/ml).
TABLE 3. Release of Aspergillus markers during in vitro growth
in Erlenmeyer flask on YNB with 100 mM of glucose
buffered at pH 7.4a
Time of growth
(h)
PA ELISA result
(EI)b
Fungitell result
(BG in pg/ml)c
PCR (Aspergillus
DNA)d
0 0.470 213.4 Neg
2 0.970 827.6 Neg
4 1.570 527.0 Neg
6 21.0 727.4 Neg
8 157.5 1,278.5 Neg
10 506.0 3,274.2 Neg
12 791.5 7,278.1 Neg
14 1,663.5 6,773.0 Neg
16 3,031.0 11,282.0 Neg
18 4,594.0 15,791.0 Neg
24 11,440.0 58,914.9 Neg
32 20,430.0 58,914.9 Neg
40 27,669.5 53,904.9 Neg
a Results are the mean values from two individual growth experiments (CAG
and CAG strains).
b Cutoff value, 0.5 ng/ml GM.
c Cutoff value, 60 pg/ml BG. The values at time zero ranged from 0 to 777
pg/ml. Values at 2, 4, and 6 h were within the same range as those at time zero.
d Neg, negative.
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release of a proton from the cell, as shown for other fungi (1,
17). This study shows that the release of GM and other galf
antigens by A. fumigatus during the logarithmic growth phase
corresponds with the increase in fungal biomass and the glu-
cose concentration used. The same is true for BG release
during the first 24 h of logarithmic growth. However, BG was
detected somewhat later than galf antigens. Furthermore, BG
showed a decrease after 24 h, which is not due to nutrient
limitation (i.e., glucose). A decrease of BG after 24 h of in vitro
growth has already been shown by Miyazaki et al. (33) for
Candida albicans and was suggested to be caused by the en-
zyme -1,3-glucanase. Those authors also measured a maxi-
mum BG release by A. fumigatus of about 10,000 pg/ml after
48 h of growth at 30°C. A. fumigatus has been shown to pro-
duce cell wall-associated exo-1,3--glucanases and an endo-
1,3--glucanase, which might have a role in cell wall mor-
phogenesis (14, 15). In other filamentous fungi, exocellular
-glucanases have also been found and seem to have a role in
hydrolyzing exocellular BGs for fungal catabolism. However,
these enzymes are expressed only under glucose limitation
(15). The BG decrease in this study is clearly enzyme related,
but it is not clear which of the glucanases is responsible.
When glucose becomes limited, mycelium is broken down.
This results in a further release of galf antigens (expressed as
GM concentration with equivalent PA ELISA reactivities). A
part of these antigens probably originate from the cell wall,
including GM and peptidoGM (25); however, other galf anti-
gens might be induced due to nutrient limitation, e.g., glucose
and phosphate. Phospholipase C, a possible virulence factor, is
repressed by phosphate (34) and might be induced by phos-
phate limitation. Together with phytase and alkaline phos-
phatase, this enzyme might be part of a phosphate-scavenging
system as suggested by Morelle et al. (34). The exact cause of
increase of PA ELISA reactivity in the culture supernatants
remains unknown because not all in vitro galf antigens and
their contributions to the total PA ELISA reactivity are char-
acterized. In addition to glucose, pH also has an influence on
the release of galf antigens. More PA ELISA reactivity is found
in the medium when it is cultured at a higher pH than at a low
pH. Galactomannan is a cell wall component that is also re-
leased in the environment, probably as a carbon overflow
mechanism (31, 40). The role of some extracellular polysac-
charides of fungi may be to reserve nutrient sources of carbon.
During C limitation, GM and other galf epitopes might be
broken down by the enzyme exo--D-galactofuranosidase to
produce galactose, which can then be used as a secondary C
source, as suggested for Aspergillus niger (57) and Penicillium
fellutanum (40). The production of this enzyme seemed to be
medium dependent, with glucose as a repressor (10). Further-
more, a galactofuranosidase was purified from A. niger with an
optimum pH of 3 to 4 (56). The results of this study suggest
that -galactofuranosidase activity is involved in the decrease
of galf epitopes in the culture supernatant. The activity rises
after glucose becomes limited and seems to be influenced by
the pH of the culture medium. As a consequence, the maxi-
mum galf antigen concentration is lower at a low pH than at a
higher pH. Furthermore, lowering the pH gives a fast decrease
of galf antigen concentration compared to buffering the me-
dium at pH 7.4 (Fig. 2 and 3). The -galactofuranosidase
activity in the culture filtrates is probably even higher because
the assay uses synthetic PNP-galf as a substrate. The purified
galactofuranosidase from Trichoderma harzianum showed a
low activity on synthetic PNP-galf, indicating that the enzyme
needs more than one galf residue for binding (53). Further-
more, the presence of galf antigens as a concurrent substrate in
the culture supernatant might also decrease the measured en-
zyme activity.
A specific -D-galactofuranosidase has been detected in only
a few species of fungi: P. fellutanum (44), Penicillum and As-
pergillus species (10), T. harzianum (53), Helminthosporium
sacchari (11), and A. niger (56). A comparison between enzyme
levels shows that A. fumigatus (this study) produced about the
same level as the Penicillium species (5 to 50 U/liter) but not as
much as A. niger (250 U/liter) (56). However, growth condi-
tions and substrates differed between different studies. The
-D-galactofuranosidase in the culture supernatant probably
has an autocatalytic role because activity increased under star-
vation conditions. A polyclonal antibody against the enzyme of
P. fellutanum showed that the enzyme was present throughout
the hyphae, including the walls (32). The production of extra-
cellular -D-galactofuranosidase by Aspergillus species could
interfere with their ability to be detected in immunoassays
because the enzyme degrades the epitopes. Similar activity
could also be used in vivo against galf components from com-
peting microorganisms, as suggested by Wallis et al. (56). This
study shows no difference in galactofuranosidase activity be-
tween CAG and CAG A. fumigatus strains, which argues
against a role of this enzyme in the cause of false-negative
reactivity.
Since galactofuranosyl residues and galactofuranosidases
are absent in mammalian species, it was suggested that galf
residues may have a role in the survival of fungi by preventing
the action of hosts’ glycosidases on fungal galf components,
including GM and the majority of extracellular proteins (52).
Marino et al. showed that the P. fellutanum peptidophospho-
galactomannan could not be detected in vitro after the addi-
tion of galactofuranosidase inhibitors (29). Furthermore, the
content of galactofuranose in the cell wall was significantly
decreased, and cell structure was strongly disturbed. This sug-
gests that the metabolism of galf components might be a target
FIG. 6. Release of GM and -galactofuranosidase during growth of
A. fumigatus on YNB medium supplemented with 5 mM (— and - - -)
or 25 mM (– –) of glucose as the carbon source. Each line is the mean
value of a CAG and a CAG strain. Media were buffered with MOPS
(170 mM) at pH 7.4 (—) or with MES (100 mM) at pH 5.0 (- - - and
– – –). () -Galactofuranosidase (U/liter); (E) GM (g/ml).
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for development of therapeutic agents, for instance, UDP-
galactopyranose mutase, which converts UDP-galactopyranose
to UDP-galf. This mutase enzyme is essential for the viability
of mycobacteria (46), and activity of the enzyme was shown
some time ago in penicillin fungus (39).
As opposed to galf components and BG, Aspergillus DNA
was not detected during the logarithmic growth phase of this
fungus in vitro. Fungal DNA seemed to be released only after
mycelium breakdown, due to autolysis caused by nutrient lim-
itation. However, not all PCR samples were positive during the
lytical phase. DNA might be below the detection limit of the
PCR test, and DNases secreted by the fungus could lower
the DNA level in the culture filtrate. The results suggest that
during invasive infection, damage of hyphae is required in
order to release fungal DNA, for instance, by human host
defense or autolysis. The actual form in which DNA circulates
in the blood of an IA patient is not known. Blood cultures are
rarely positive and could result only from viable hyphal frag-
ments because conidia are not present in the blood. So the
most likely circulating form seems to be free DNA (i.e., naked
DNA or DNA bound to fungal cell walls), also suggested by
Costa et al. (9). Furthermore, Bougnoux and coworkers
showed that intravenously injected Candida DNA is detectable
in rabbit serum for hours, which argues against a rapid degra-
dation of foreign DNA in the blood (3).
The form that circulates has a consequence for the DNA
isolation method used for PCR. Our results showed that the
method normally used for pretreatment of fungal mycelium in
order to release DNA resulted in the loss of free DNA after
pretreatment of PCR-positive culture filtrate samples. Further-
more, many DNA extraction methods result in decanting of
free DNA. This could explain the fact that especially antifungal
therapy, which probably releases much free DNA, is often
combined with negative PCR results (7, 22, 23). In contrast,
Kami et al. used an extraction method that includes free DNA
and found no negative PCRs in sera from patients receiving
antifungal therapy (18). In conclusion, two extraction methods
should be used on EDTA whole-blood samples, one setup to
isolate free DNA and another to isolate DNA from fungal
cells, in order to include all possible forms of circulating DNA.
During an early stage of fungal infection, detection of cir-
culating galf antigens seems to be superior to that of PCR and
BG because of much higher amounts that are released. How-
ever, other factors play a role, for instance, the level of host
defense, the ease by which the antigen reaches the circulation,
and its circulating half-lives. Many studies have been per-
formed to compare the different diagnostic methods for detec-
tion of circulating markers. While some studies show that the
PA ELISA was more frequently positive (2, 8, 47, 54), other
studies seem to be in favor of DNA detection (6, 18). The
combination of PCR with the PA ELISA should improve the
diagnosis of IA, as also suggested by other authors (4, 7, 8, 47).
Only a limited number of comparative studies have been per-
formed with the BG test (18, 19, 42). In a prospective com-
parison between the diagnostic potentials of real-time PCR,
the PA ELISA, and the BG test for IA in hematological pa-
tients, the PA ELISA was the most sensitive, using a reduced
cutoff of 0.6 ng/ml GM (19). Another study retrospectively
compared the BG test with the PA ELISA and showed im-
proved specificity when the two tests were combined (42).
However, the usefulness of the BG test for early diagnosis of
IA remains to be determined.
This study suggests that during invasive infection, the con-
ditions at the infection site may determine the actual amounts
of galf antigens, DNA, and BG that are released. Further
studies will be focused on in vitro experiments with nutrients
that mimic the clinical situation, for instance, lung proteins,
and in vivo (animal) experiments in order to determine the
conditions at the infection site and their impact on the release
of surrogate markers.
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